Prevalence of HPV and pathological changes among women 70 years of age, 10 years after exclusion from the Swedish cervical cancer screening program

Cancer Causes & Control - Tập 31 Số 4 - Trang 377-381 - 2020
Lovisa Bergengren1, Mats G. Karlsson2, Gisela Helenius2
1Deparment of Women's Health, Faculty of Medicine and Health, Örebro University, 701 85, Örebro, Sweden
2Deparment of Laboratory Medicine, Faculty of Medicine and Health, Örebro University, 701 85, Örebro, Sweden

Tóm tắt

Abstract Purpose Örebro County introduced an updated screening program 2016 with primary HPV test for women over 30 years and prolonged screening, increasing the cut-off age from 56–60 to 64–70. The aim of this study was to investigate the prevalence of HPV genotypes and their correlation to histological changes in women, 10 years after exclusion from the screening program, due to an eventual implementation of a catch-up program including all women aged 60–70. Methods All women in Örebro County, born 1,946 (n = 1,968), were invited to a liquid-based cell sample with primary HPV screening. Samples were analyzed for hrHPV mRNA and positive samples were genotyped. hrHPV positive women were offered to do a conization. Results Out of 809 participants, 31 (3.8%) were hrHPV positive, of these 22 did a conization. Histologically, 5/22 (23%) had LSIL and 5/22 (23%) had HSIL. Normal histology was found in 12/22 (55%). The most prevalent genotypes were HPV 16, 33, 52, 56, and 68. Of the women with HSIL, one case of cervical cancer was confirmed in a recone biopsy after 4 months. Conclusion The study showed considerable prevalence of hrHPV and histologically confirmed LSIL/HSIL. These data led to catch-up screening for women between 60 and 70 years when overlapping two screening strategies.

Từ khóa


Tài liệu tham khảo

Bergengren L, Lillsunde-Larsson G, Helenius G, Karlsson MG (2019) HPV-based screening for cervical cancer among women 55–59 years of age. PLoS ONE 14(6):e0217108. https://doi.org/10.1371/journal.pone.0217108

Bonde J, Rebolj M, Ejegod DM, Preisler S, Lynge E, Rygaard C (2014) HPV prevalence and genotype distribution in a population-based split-sample study of well-screened women using CLART HPV2 human papillomavirus genotype microarray system. BMC Infect Dis 14:413. https://doi.org/10.1186/1471-2334-14-413

Wright TC Jr, Stoler MH, Behrens CM, Apple R, Derion T, Wright TL (2012) The ATHENA human papillomavirus study: design, methods, and baseline results. Am J Obstet Gynecol. 206(1):46.e1–46.e11. https://doi.org/10.1016/j.ajog.2011.07.024

Brotherton JM, Hawkes D, Sultana F, Malloy MJ, Machalek DA, Smith MA et al (2019) Age-specific HPV prevalence among 116,052 women in Australia's renewed cervical screening program: a new tool for monitoring vaccine impact. Vaccine 37(3):412–416. https://doi.org/10.1016/j.vaccine.2018.11.075

Bergstrom R, Sparen P, Adami HO (1999) Trends in cancer of the cervix uteri in Sweden following cytological screening. Br J Cancer 81(1):159–166. https://doi.org/10.1038/sj.bjc.6690666

Vaccarella S, Franceschi S, Engholm G, Lonnberg S, Khan S, Bray F (2014) 50 years of screening in the Nordic countries: quantifying the effects on cervical cancer incidence. Br J Cancer 111(5):965–969. https://doi.org/10.1038/bjc.2014.362

Gustafsson L, Ponten J, Bergstrom R, Adami HO (1997) International incidence rates of invasive cervical cancer before cytological screening. Int J Cancer 71(2):159–165

Welfare TNBoHa. Socialstyrelsen (2019) https://www.socialstyrelsen.se/statistik/statistikdatabas/cancer. Accessed 27 May 2019

Welfare TNBoHa. Statistikdatabas dödsorsaker: The National Board of Health and Welfare (2018) https://www.socialstyrelsen.se/statistik/statistikdatabas/dodsorsaker. Accessed 2018

Lonnberg S, Anttila A, Luostarinen T, Nieminen P (2012) Age-specific effectiveness of the Finnish cervical cancer screening programme. Cancer Epidemiol Biomarkers Prev 21(8):1354–1361. https://doi.org/10.1158/1055-9965.epi-12-0162

Socialstyrelsen. Screening för livmoderhalscancer – Rekommendation och bedomningsunderlag. Artikelnr 2015-6-39. https://www.socialstyrelsen.se/Lists/Artikelkatalog/Attachments/19873/2015-6-39.pdf. Accessed june 2015

zur Hausen H (2009) Papillomaviruses in the causation of human cancers—a brief historical account. Virology 384(2):260–265. https://doi.org/10.1016/j.virol.2008.11.046

Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV et al (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189(1):12–19. https://doi.org/10.1002/(sici)1096-9896(199909)189:1%3c12:aid-path431%3e3.0.co;2-f

Wang J, Andrae B, Sundstrom K, Ploner A, Strom P, Elfstrom KM et al (2017) Effectiveness of cervical screening after age 60 years according to screening history: nationwide cohort study in Sweden. PLoS Med 14(10):e1002414. https://doi.org/10.1371/journal.pmed.1002414

Darlin L, Borgfeldt C, Widen E, Kannisto P (2014) Elderly women above screening age diagnosed with cervical cancer have a worse prognosis. Anticancer Res 34(9):5147–5151

Andrae B, Kemetli L, Sparen P, Silfverdal L, Strander B, Ryd W et al (2008) Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. J Natl Cancer Inst 100(9):622–629. https://doi.org/10.1093/jnci/djn099

World Health Organization, International Agency for Research on Cancer (2014) WHO Classification of Tumours of Female Reproductive Organs [Elektronisk resurs]. International Agency for Research on Cancer, Lyon

cervixcancerprevention Sffooga-orf. Cervixcancerprevention 2010. https://www.sfog.se/natupplaga/nr6393f53d8d-2b98-4cdf-a05a-aca202db2496.pdf. Accessed 7 Jan 2020

Hermansson RS, Olovsson M, Hoxell E, Lindstrom AK (2018) HPV prevalence and HPV-related dysplasia in elderly women. PLoS ONE 13(1):e0189300. https://doi.org/10.1371/journal.pone.0189300

Lamin H, Eklund C, Elfstrom KM, Carlsten-Thor A, Hortlund M, Elfgren K et al (2017) Randomised healthcare policy evaluation of organised primary human papillomavirus screening of women aged 56–60. BMJ Open 7(5):e014788. https://doi.org/10.1136/bmjopen-2016-014788

Asciutto KC, Forslund O, Borgfeldt C (2018) Prevalence of high-risk HPV in postmenopausal women with benign cervical cytology—a population-based cohort study. Anticancer Res 38(7):4221–4228. https://doi.org/10.21873/anticanres.12718

Tifaoui N, Maudelonde T, Combecal J, Vallo R, Doutre S, Didelot MN et al (2018) High-risk HPV detection and associated cervical lesions in a population of French menopausal women. J Clin Virol 108:12–18. https://doi.org/10.1016/j.jcv.2018.08.010

Brogaard KA, Munk C, Iftner T, Frederiksen K, Kjaer SK (2014) Detection of oncogenic genital human papillomavirus (HPV) among HPV negative older and younger women after 7 years of follow-up. J Med Virol 86(6):975–982. https://doi.org/10.1002/jmv.23914

Larsen MB, Mikkelsen EM, Jeppesen U, Svanholm H, Andersen B (2017) The influence of total hysterectomy in a cervical cancer screening population: a register-based cross-sectional study. BMC Health Serv Res 17(1):423. https://doi.org/10.1186/s12913-017-2371-4

Lam JU, Lynge E, Njor SH, Rebolj M (2015) Hysterectomy and its impact on the calculated incidence of cervical cancer and screening coverage in Denmark. Acta Oncol 54(8):1136–1143. https://doi.org/10.3109/0284186x.2015.1016625

Castañón A, Landy R, Cuzick J, Sasieni P (2014) Cervical screening at age 50–64 years and the risk of cervical cancer at age 65 years and older: population-based case control study. PLoS Med. https://doi.org/10.1371/journal.pmed.1001585

Gustafsson L, Sparen P, Gustafsson M, Pettersson B, Wilander E, Bergstrom R et al (1995) Low efficiency of cytologic screening for cancer in situ of the cervix in older women. Int J Cancer 63(6):804–809

Elfgren K, Elfstrom KM, Naucler P, Arnheim-Dahlstrom L, Dillner J (2017) Management of women with human papillomavirus persistence: long-term follow-up of a randomized clinical trial. Am J Obstet Gynecol 216(3):264.e1–264.e7. https://doi.org/10.1016/j.ajog.2016.10.042

Thông tin
Thông tin xuất bản

Cancer Causes & Control

Tập 31 Số 4

377-381

Thông tin tác giả